Clinical Trials Logo

Refractory Tumor clinical trials

View clinical trials related to Refractory Tumor.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06456138 Not yet recruiting - Clinical trials for Advanced Lung Cancer

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Start date: July 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Lung cancer is the most common cause of cancer-related death worldwide. Approximately 85% to 90% of lung cancer cases are non-small cell lung cancer (NSCLC), of which KRAS is one of the most common driver genes, occurring in 25-30% of lung adenocarcinomas and 3-5% of squamous cell carcinomas. KRAS-mutant NSCLC had been considered undruggable in past decades. This research sought to address a significant challenge in treating NSCLC with KRAS mutations, which are notoriously difficult to target effectively. Here, we proposal that the combined use of anlotinib and trametinib combined with tislelizumab may form an effective strategy for the treatment of KRAS-mutant NSCLC patients.